CAM
CNTA

Cormorant Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Cormorant Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.7M Sell
1,050,000
-275,000
-21% -$7.03M 2.09% 15
2025
Q4 		$33.1M Sell
1,325,000
-600,000
-31% -$15.2M 1.53% 19
2025
Q3 		$46.7M Sell
1,925,000
-161,600
-8% -$2.87M 3.22% 12
2025
Q2 		$27.4M Sell
2,086,600
-175,000
-8% -$2.22M 2.04% 15
2025
Q1 		$32.5M Sell
2,261,600
-300,000
-12% -$4.91M 2.45% 12
2024
Q4 		$42.9M Hold
2,561,600
– – 2.36% 12
2024
Q3 		$41M Buy
2,561,600
+950,000
+59% +$11.6M 2.17% 15
2024
Q2 		$14.6M Buy
1,611,600
+1,050,000
+187% +$9.96M 0.84% 32
2024
Q1 		$6.35M Hold
561,600
– – 0.28% 50
2023
Q4 		$4.47M Hold
561,600
– – 0.21% 43
2023
Q3 		$3.63M Hold
561,600
– – 0.21% 41
2023
Q2 		$3.48M Hold
561,600
– – 0.19% 54
2023
Q1 		$2.16M Hold
561,600
– – 0.14% 59
2022
Q4 		$1.74M Sell
561,600
-1,411,128
-72% -$5.23M 0.12% 61
2022
Q3 		$7.93M Sell
1,972,728
-954,545
-33% -$4.37M 0.55% 44
2022
Q2 		$14.3M Buy
2,927,273
+437,379
+18% +$2.8M 1.08% 32
2022
Q1 		$22.3M Hold
2,489,894
– – 1.71% 17
2021
Q4 		$28M Buy
2,489,894
+762,621
+44% +$10.3M 1.67% 20
2021
Q3 		$28.7M Buy
1,727,273
+300,000
+21% +$6.21M 1.17% 27
2021
Q2 		$31.1M Buy
+1,427,273
New +$33.5M 1.05% 28

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Cormorant Asset Management's CNTA Position: Q1 2026 in Review

Cormorant Asset Management reduced its Centessa Pharmaceuticals (CNTA) stake by 21% in Q1 2026, selling an estimated $7.03M and leaving 1,050,000 shares worth $41.7M. The position accounts for 2.09% of the portfolio, ranked #15.

Cormorant Asset Management first reported a position in CNTA in Q2 2021 and has held it in 20 quarters since. The position peaked at $46.7M in Q3 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Cormorant Asset Management held 1,050,000 shares of Centessa Pharmaceuticals worth $41.7M as of Q1 2026.
  • Cormorant Asset Management sold 275,000 Centessa Pharmaceuticals shares in Q1 2026, an estimated $7.03M.
  • Centessa Pharmaceuticals made up 2.09% of Cormorant Asset Management's portfolio in Q1 2026, its #15 holding.
  • Cormorant Asset Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Cormorant Asset Management's Centessa Pharmaceuticals position peaked at $46.7M in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.